Method for detecting carcinomas in a solubilized cervical...

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S007920, C436S064000, C436S501000, C530S350000, C530S387700, C530S389700

Reexamination Certificate

active

10650057

ABSTRACT:
The present invention relates to a method for the early diagnosis of carcinomas and their preliminary stages, which comprises determining the overexpression of a cell cycle regulatory protein in a solubilized body sample. The present invention is particularly directed to a method for detecting cervical carcinomas, cervical intraepithelial neoplasias, or cervical carcinomas in-situ from a solubilized cervical body sample of a human subject, by solubilizing the cervical body sample in a lysis buffer, and determining the overexpression of cyclin dependent kinase inhibitor p16 in the solubilized cervical sample. The invention also concerns a test kit usable for this purpose as well as an in-vitro diagnostic device.

REFERENCES:
patent: 4281061 (1981-07-01), Zuk et al.
patent: 5889169 (1999-03-01), Beach et al.
patent: 6033847 (2000-03-01), Sherr et al.
patent: 6316208 (2001-11-01), Roberts et al.
patent: 6403383 (2002-06-01), Casterlin et al.
patent: 6709832 (2004-03-01), Von Knebel Doeberitz et al.
patent: 2001/0039023 (2001-11-01), Schubert
patent: 2002/0086288 (2002-07-01), Bird et al.
patent: 2003/0157482 (2003-08-01), Keesee et al.
patent: 0 723 156 (1995-12-01), None
patent: 1 217 377 (2001-12-01), None
patent: WO/9220796 (1992-11-01), None
patent: WO 99/04238 (1998-07-01), None
Geradts et al. (Am. J. Pathol. Jun. 1999; 154 (6): 1665-1671).
Ryder et al. (Clin. Chem. Dec. 1988 34 (12): 2513-2516).
Khleif et al. (Proc. Natl. Acad. Sci. USA. Apr. 1996 93: 4350-4354).
Sano et al. (Pathology International. 1998; 48: 580-585).
Ikeda et al. (J. Histochem. Cytochem. 1998; 46 (3): 397-403).
Wentzensen et al. Cancer. 2006; 107: 2307-13.
Mao et al. Int. J. Cancer. 2007; 120: 2435-8.
Suneja et al. Brain Res. Protocols. 1998; 3: 88-93.
Castellano et al. Cancer Res. Nov. 1, 1997; 57: 4868-75.
Plath et al. J. Cell Biol. Sep. 18, 2000; 150 (6): 1467-77.
Gump et al. J. Biol. Chem. Feb. 28, 2003; 278 (9): 6619-22.
Dai et al. Gastroenterology. 2000; 119: 929-42.
Qualtiere et al. (J. Immunol. Nov. 1977; 119(5): 1645-1651).
Dimitriadis et al. (Anal. Biochem. Oct. 1, 1979; 98 (2): 445-451).
McCabe et al. (J. Immunol. Methods. Apr. 6, 1988; 108 (1-2): 129-135).
Bhakdi (J. Biochem. Biophys. Methods. Jan.-Feb. 2, 1980; 2 (1): 79-90).
Liggett et al. (J. Clin. Oncol. Mar. 1998;16 (3): 1197-1206).
Geradts, et al., “Immunohistochemical Detection of the Cyclin-dependent Kinase Inhibitor 2/Multiple Tumor Suppressor Gene 1 (CDKN2/MTS1) Productp16INK4Ain Archival Human Solid Tumors: Correlation with Retinoblastoma Protein Expression”,Cancer Research55: 6006-11 (1995).
Hirama, et al., “p16 (CDKN2/Cylin-dependent Kinase-+inhibitor/Multiple Tumor Suppressor-1) Gene Is Not Altered in Uterine Cervical Carcinomas or Cell Lines”,Modern Pathology, 9(1) 26-31 (1996).
Kelley, et al., “CDKN2 in HPV-Positive and HPV-Negative Cervical-Carcinoma Cell Lines”,Int. J. Cancer, 63: 226-30 (1995).
Kim, et al., “Absence ofp15INK4Bandp16INK4AGene Alterations in Primary Cervical Carcinoma Tissues and Cell Lines with Human Papillomavirus Infection”,Gynecologic Oncology, 70: 75-9 (1998).
Kim, et al., “Underexpression of Cyclin-Dependent Kinase (CDK) Inhibitors in Cervical Carcinoma”,Gynecologic Oncology, 71: 38-45 (1998).
Klaes, et al., “Overexpression ofp16INK4Aas a Specific Marker for Dysplastic and Neoplastic Epithelial Cells of the Cervix Uteri”,Int. J. Cancer, 92: 276-284 (2001).
Milde-Langosch, et al., “P16/MTS1 andpRB expression in endometrial carcinomas”,Virchows Arch, 434: 23-8 (1999).
Milde-Langosch, et al.,p16/MTS1 Inactivation in Ovarian Carcinomas: High Frequency of rEduced.
Protein expression Associated with Hyper-Methylation or Mutation in Endometroid and Mucinous Tumors ,Int. J. Cancer, 79: 61-5 (1998).
Nuovo, et al., “In situ detection of the hypermethylation-induced inactivation of thep16 gene as a early event in oncogenesis”,PNAS, 96(22): 12754-9 (1999).
Sano, et al., “Expression Status ofp16 Protein Is Associated with Human Papillomavirus Oncogenic Potential in Cervical and Genital Lesions”,American Journal of Pathology, 153(6): 1741-8 (1998).
Sano, et al., “Immunohistochemical overexpression ofp16 protein associated with intact retinoblastoma protein expression in cervical cancer and cervical intraepithelial neoplasia”,Pathology International, 48: 580-5 (1998).
Serrano, et al., “A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4”,Nature, 366: 704-7 (1993).
Shigemasa, et al., “p16 Overexpression: A Potential Early Indicator of Transformation in Ovarian Carcinoma”,J. Soc. Gynecol Invest., 4(2): 95-102 (1997).
Shim, et al., “Profiling of Differentially Expressed Genes in Human Primary Cervical Cancer by Complementary DNA Expression Array”,Clinical Cancer Research, 4: 3045-50 (1998).
Tam, et al., “Differential Expression and Cell Cycle Regulation of the Cyclin-dependent Kinase 4 Inhibitorp16INK4”,Cancer Research, 54: 1816-20 (1994).
Wong, et al., “Methylation ofp16INK4Ain primary gynecologic malignancy”,Cancer Letters, 136: 231-5 (1999).
Wong, et al.,p16INK4andp15INK4BAlterations in Primary Gynecologic Malignancy,Gynecologic Oncology65: 319-24 (1997).
He, et al., “Expression, Deletion And Mutation of p16 Gene in Human Gastric Cancer”World J. of Gastroenterology7(4): 515-521 (2001).
Myung, et al., “Loss Of p16 And p27 Is Associated With Progression Of Human Gastric Cancer”Cancer Letters153:129-136 (2000).
Nakao et al., “Induction of p16 During Immortalization HPV 16 and 18 and Not During Malignant Transformation”British J of Cancer75(10):1410- 1416, 1997.
O'Nions, et al., “p73 Is Over-Expressed In Vulval Cancer Principally As The Δ2 Isoform”British J. Cancer85(10):1551-1556 (Nov. 2001).
Sano, et al., “Overexpression Of p16 And P14ARF Is Associated With Human Papillomavirus Infection In Cervical Squamous Cell Carcinoma And Dysplasia”Pathology Int.52:375-383 (May 2002).
Sherr, “The Ink4a/Arf Network in Tumor Suppression”Nature Reviews Mol. Cell Bio2:731-737, (2001).
Takeuchi, et al., “Altered p16/MTSi/CDKN2 and Cycling D1/PRAD-1 Gene Expression Is Associated With The Prognosis of Squamous Cell Carcinoma of the Esophagus”Clinical Cancer Research3:2229-2236, (1997).
Tsujie, et al., “Expression of Tumor Suppressor Gene p16INK4 Products in Primary Gastric Cancer”Oncology58:126-136 (2000).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Method for detecting carcinomas in a solubilized cervical... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for detecting carcinomas in a solubilized cervical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for detecting carcinomas in a solubilized cervical... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3846257

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.